On March 7, 2018 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, reported that company management will present at two investor conferences in March (Press release, Iovance Biotherapeutics, MAR 7, 2018, View Source;p=RssLanding&cat=news&id=2336749 [SID1234524508]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen 38th Annual Health Care Conference in Boston, MA on Wednesday, March 14, 2018 at 10:40 a.m. ET
Oppenheimer’s 28th Annual Healthcare Conference in New York, NY on Wednesday, March 21, 2018 at 11:30 a.m. ET
A live audio webcast of both presentations will be available by visiting the Investors section of Iovance Biotherapeutics’ website at View Source A replay of the webcasts will be archived on Iovance Biotherapeutics’ website for 30 days following the presentations.

On March 7, 2018 LabCorp (NYSE: LH) reported it will participate at the 2018 Barclays Global Healthcare Conference. LabCorp’s presentation is planned for Wednesday, March 14, 2018 at 9:30 am (ET) (Press release, LabCorp, MAR 7, 2018, View Source;p=RssLanding&cat=news&id=2336875 [SID1234524510]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay.

On March 6, 2018 Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, reported that the company will present at the Cowen and Company 38th Annual Health Care Conference 2018 in Boston, Massachusetts (Press release, Constellation Pharmaceuticals, MAR 6, 2018, View Source [SID1234524412]). The presentation is scheduled for Tuesday, March 13, at 11:20 a.m. Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be available live and 30 days following the event. The webcast may be accessed via the conference website and from the investor relations section of the Corvus website

On March 6, 2018 Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, reported that the company will present at the Cowen and Company 38th Annual Health Care Conference 2018 in Boston, Massachusetts (Press release, Corvus Pharmaceuticals, MAR 6, 2018, View Source;p=RssLanding&cat=news&id=2336475 [SID1234524442]). The presentation is scheduled for Tuesday, March 13, at 11:20 a.m. Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be available live and 30 days following the event. The webcast may be accessed via the conference website and from the investor relations section of the Corvus website.

On March 6, 2018 Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) reported that Bill Lis, chief executive officer, will present at the following conferences in March (Press release, Portola Pharmaceuticals, MAR 6, 2018, View Source;p=RssLanding&cat=news&id=2336594 [SID1234524461]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen and Company’s 38th Annual Health Care Conference on Tuesday, March 13, 2018, at 8:40 a.m. Eastern Time in Boston.
Oppenheimer’s 28th Annual Healthcare Conference on Tuesday, March 20, 2018, at 10:55 a.m. Eastern Time in New York.
Both presentations will be webcast live and available for replay from Portola’s website at www.portola.com in the Investor Relations section.